Posts | Comments

Global Heart Failure Disease Market Growth

Contact Us
Nick Thomas
British Columbia V4C3B8 

According to MarkNtel Advisors’ research report titled “Global Heart Failure Disease Market Analysis, 2020”, the Global Heart Failure Disease market is anticipated to grow at a CAGR of around 12.5% during 2020-25. Based on age, above 65 age group captured the majority market share in the Global Heart Failure market in 2020 owing to a booming ageing population globally making it more prone to acquire various diseases such as diabetes and high blood pressure. Heart failure is among the leading reasons for hospitalizations in adults who are 65 years or older.

“Global Heart Failure Disease Market Analysis, 2020” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and growth opportunities available for Heart Failure Disease providers across the globe. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor’s capabilities on 16 parameters. This will help companies in the formulation of Go to Market Strategies and identifying the blue ocean for its offerings.

North America Accounted for the Substantial Market Share
North America acquired the significant market share in 2019. US dominated the North America market and is expected to continue is dominance in the near future on high prevalence of heart failure among the people. The burgeoning number of patients with high blood pressure and diabetesis the leading cause of heart failure diseases in the country. In addition, growth in the ageing population, significant presence of market players, and high cost associated with the treatment of the disease is expectedto propel the growth of the Heart Failure Disease market in the forthcoming years as stated in the MarkNtel Advisors’ research report “Global Heart Failure Disease Market Analysis, 2020”.

According to MarkNtel Advisors, the key players with a considerable market share in the Global Heart Failure Disease market are Astra Zeneca, Bayer, Bristol-Myers Squibb, Cytokinetics, Amgen, Merck, Novartis, Renova Therapeutics, Servier, Stealth Bio Therapeutics, Pfizeretc.

Market Segmentation:
1. By Treatment Type (Drug (Beta Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers, Diuretics, Inotropic Agents, Aldosterone Antagonist, Calcium Channel Blockers, Others (Milrinone and Flosequinan, etc.), Surgery, Medical Devices (Ventricular Assist Device (VAD), Pacemaker, Implantable Cardioverter-Defibrillators (ICD), Continuous Positive Air Pressure Device (CPAP), Bi-Level Positive Air Pressure Device (BiPAP), Heart Pumps))
2. By Gender (Male, Female)
3. By Age Group (Upto30 years, 31-64 years, Above 65 years)
4. By Diagnostic Test (Blood Test, Electrocardiogram (ECG), Echocardiogram, Chest X-ray, CT Scan & MRI, Others (Myocardial Biopsy, stress test, etc)
5. By Region (North America, South America, Europe, Asia-Pacific, Middle East & Africa)
6. By Country (US, Canada, Mexico, Brazil, Argentina, UK, Germany, Italy, France, Spain, the Netherlands, China, Japan, South Korea, India, South-East Asia, Australia, UAE, Saudi Arabia, South Africa),
7. By Company (AstraZeneca, Bayer, Bristol-Myers Squibb, Cytokinetics, Amgen, Merck, Novartis, Renova Therapeutics, Servier, Stealth BioTherapeutics, Pfizeretc.)

Key questions answered in the study:
1. What are the current and future trends of the Heart Failure Disease industry?
2. How the industry has been evolving in terms of end-user demand and application areas?
3. How the competition has been shaping across the countries followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the Heart Failure Disease industry?
5. What is the customer orientation, purchase behavior, and expectations from the Heart Failure Disease firms across various regions?

Leave a Reply